ANGPTL3 and metabolic syndrome: For example, Vupanorsen, an ASO drug that inhibits the synthesis of Angiopoietin-like 3 (ANGPTL3) protein, demonstrated a notable reduction in non-HDL cholesterol levels in patients with dyslipidemia under statin treatment [246].